Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 30
Filtrer
1.
Glob Health Med ; 6(4): 277-281, 2024 Aug 31.
Article de Anglais | MEDLINE | ID: mdl-39219588

RÉSUMÉ

This study aimed to establish a standard treatment for disseminated extranodal large B-cell lymphoma, including intravascular large B-cell lymphoma (DEN-LBCL/IVL), and to validate the clinical diagnostic criteria we proposed. Between 2006 and 2016, 22 patients were enrolled in a clinical trial conducted by the Hokuriku Hematology Oncology Study Group. The first cycle of chemotherapy consisted of dose-reduced cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with delayed administration of rituximab. From the second to the sixth cycle, patients received conventional rituximab and CHOP therapy. The primary endpoint was overall survival (OS), while the secondary endpoints included the complete response (CR) rate and time to treatment failure (TTF). The results showed a CR rate of 73%, a median OS of 65 months, and a median TTF of 45 months. These findings indicate that patients with DEN-LBCL/IVL were effectively treated with our new chemoimmunotherapy regimen. Our clinical diagnostic criteria are useful for identifying patients who require early intervention.

2.
Immunol Med ; 47(3): 192-199, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-38619098

RÉSUMÉ

Hemophagocytic lymphohistiocytosis (HLH) has been recognized as a rare adverse event following the coronavirus disease 2019 (COVID-19) vaccination. We report a case of neuropsychiatric symptoms and refractory HLH in a woman with systemic lupus erythematosus (SLE) after receiving her COVID-19 vaccine treated with belimumab, later found to have intravascular large B-cell lymphoma (IVLBCL) at autopsy. A 61-year-old woman with SLE was referred to our hospital because of impaired consciousness and fever. One month prior to consulting, she received her second COVID-19 vaccine dose. Afterward, her consciousness level decreased, and she developed a high fever. She tested negative for SARS-CoV-2. Neuropsychiatric SLE was suspected; therefore, glucocorticoid pulse therapy was initiated on day 1 and 8. She had thrombocytopenia, increased serum ferritin levels and hemophagocytosis. The patient was diagnosed with HLH and treated with etoposide, dexamethasone and cyclosporine. Despite treatment, the patient died on day 75; autopsy report findings suggested IVLBCL as the underlying cause of HLH. Differentiating comorbid conditions remains difficult; however, in the case of an atypical clinical presentation, other causes should be considered. Therefore, we speculate that the COVID-19 vaccination and her autoimmune condition may have expedited IVLBCL development.


Sujet(s)
Vaccins contre la COVID-19 , COVID-19 , Lupus érythémateux disséminé , Lymphohistiocytose hémophagocytaire , Lymphome B diffus à grandes cellules , SARS-CoV-2 , Humains , Lymphohistiocytose hémophagocytaire/étiologie , Femelle , Lupus érythémateux disséminé/complications , Adulte d'âge moyen , Issue fatale , COVID-19/complications , Lymphome B diffus à grandes cellules/traitement médicamenteux , Vaccins contre la COVID-19/effets indésirables , Vaccins contre la COVID-19/administration et posologie , Vaccination/effets indésirables , Dexaméthasone/administration et posologie , Dexaméthasone/usage thérapeutique
3.
Intern Med ; 62(1): 27-32, 2023 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-35598998

RÉSUMÉ

TAFRO syndrome was first described in 2010, standing for thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly. Because the lymph node histopathology of TAFRO syndrome mimics idiopathic multicentric Castleman disease (iMCD), some researchers consider TAFRO syndrome to be a subtype of iMCD. However, the clinical features of TAFRO syndrome considerably differ from those of iMCD without TAFRO. The clinical features of patients with TAFRO syndrome with or without iMCD-histopathology are similar, and these patients require an accurate diagnosis and urgent treatment. Although a histological diagnosis, including a differential diagnosis, is important, lymph node involvement in patients with TAFRO syndrome is usually modest or sometimes absent. Furthermore, a bleeding tendency due to thrombocytopenia and severe anasarca hampers performing a biopsy. Nonetheless, patients with various other disorders may manifest TAFRO syndrome-like symptoms, making the differential diagnosis in borderline cases difficult. Therefore, the establishment of precise and specific biomarkers is important.


Sujet(s)
Hyperplasie lymphoïde angiofolliculaire , Thrombopénie , Humains , Hyperplasie lymphoïde angiofolliculaire/anatomopathologie , Noeuds lymphatiques/anatomopathologie , Thrombopénie/traitement médicamenteux , Oedème/diagnostic , Oedème/étiologie , Oedème/traitement médicamenteux
4.
Case Rep Oncol ; 15(2): 535-540, 2022.
Article de Anglais | MEDLINE | ID: mdl-35813699

RÉSUMÉ

Chronic myeloid leukemia (CML) blast phase (monocytic lineage) is extremely rare. A 39-year-old Japanese man was diagnosed with CML blast phase (monocytic lineage). T315I mutation was positive, ponatinib was initially started, and then, allogenic hematopoietic stem cell transplantation (allo-HSCT) was performed. Seven days after allo-HSCT, hyper-acute graft-versus-host disease developed, and medial temporal lobe encephalitis emerged 24 days after allo-HSCT. He was alive for over 1 year after allo-HSCT. This is the first case report of HSCT for CML blast phase (monocytic lineage) in tyrosine kinase inhibitor era. Further cases should be documented for effective treatment regimen and analysis of clinical features.

6.
Int J Hematol ; 116(1): 81-88, 2022 Jul.
Article de Anglais | MEDLINE | ID: mdl-35318539

RÉSUMÉ

Various systems for predicting the prognosis of patients with myelodysplastic syndromes (MDS) have been developed. However, associations between performance status (PS) and prognosis of MDS require further investigation. To objectively assess the impact of PS on survival, we examined laboratory findings associated with PS, including serum levels of C-reactive protein (CRP), albumin (ALB), and total cholesterol (CHOL). Patients (n = 123; male 86, female 37; median age 74 yrs.) diagnosed with MDS or myelodysplastic/myeloproliferative neoplasms at Kanazawa Medical University Hospital between 2010 and 2020 were enrolled and grouped by cutoff values determined by receiver operating characteristic analysis: 0.44 mg/dL for CRP, 4.0 g/dL for ALB, and 120 mg/dL for CHOL. The median follow-up period was 17.6 months. Kaplan-Meier analysis revealed that overall survival (OS) in the high CRP, low ALB, and low CHOL groups was significantly shorter than in the low CRP, high ALB, and high CHOL groups, respectively. Multivariable analysis revealed that elevated serum CRP was an independent prognostic risk factor independent of gender, bone marrow blast percentage, and cytogenetics.


Sujet(s)
Protéine C-réactive , Syndromes myélodysplasiques , Sujet âgé , Protéine C-réactive/analyse , Femelle , Humains , Estimation de Kaplan-Meier , Mâle , Syndromes myélodysplasiques/diagnostic , Pronostic , Études rétrospectives , Sérumalbumine/analyse
7.
Ann Hematol ; 101(3): 485-490, 2022 Mar.
Article de Anglais | MEDLINE | ID: mdl-35044513

RÉSUMÉ

Although Castleman disease was first described in 1956, this disease includes various conditions, including unicentric Castleman disease with hyaline vascular histology, human herpesvirus-8 (HHV-8) related multicentric Castleman disease, idiopathic multicentric Castleman disease, and mimics of Castleman disease associated with other conditions. To date, Castleman disease remains incompletely understood due to its rareness and difficulties in clinical and pathological diagnosis. TAFRO syndrome was reported in Japan in 2010. Because lymph node histology is similar in patients with TAFRO syndrome and Castleman disease, TAFRO syndrome is described as a related disorder of Castleman disease. Clinically, however, these conditions differ markedly. Although elevated interleukin-6 (IL-6) expression is characteristic of Castleman disease, increased expression of IL-6 may occur in patients with other diseases, making elevated IL-6 unsuitable for differential diagnosis. Further understanding of these disorders requires the identification of novel disease-specific biomarkers. This review article therefore outlines the characteristics of Castleman disease and TAFRO syndrome.


Sujet(s)
Hyperplasie lymphoïde angiofolliculaire/diagnostic , Animaux , Hyperplasie lymphoïde angiofolliculaire/sang , Hyperplasie lymphoïde angiofolliculaire/anatomopathologie , Syndrome de libération de cytokines/sang , Syndrome de libération de cytokines/diagnostic , Syndrome de libération de cytokines/anatomopathologie , Diagnostic différentiel , Humains , Interleukine-6/analyse , Interleukine-6/sang , Noeuds lymphatiques/anatomopathologie
9.
Sci Rep ; 9(1): 18094, 2019 12 02.
Article de Anglais | MEDLINE | ID: mdl-31792328

RÉSUMÉ

Dipeptidyl peptidases (DPPs) are proteolytic enzymes that are ideal therapeutic targets in human diseases. Indeed, DPP4 inhibitors are widely used in clinical practice as anti-diabetic agents. In this paper, we show that DPP4 inhibitors also induced cell death in multiple human myeloma cells. Among five DPP4 inhibitors, only two of them, vildagliptin and saxagliptin, exhibited apparent cytotoxic effects on myeloma cell lines, without any difference in suppression of DPP4 activity. As these two DPP4 inhibitors are known to have off-target effects against DPP8/9, we employed the specific DPP8/9 inhibitor 1G244. 1G244 demonstrated anti-myeloma effects on several cell lines and CD138+ cells from patients as well as in murine xenograft model. Through siRNA silencing approach, we further confirmed that DPP8 but not DPP9 is a key molecule in inducing cell death induced by DPP8/9 inhibition. In fact, the expression of DPP8 in CD38+ cells from myeloma patients was higher than that of healthy volunteers. DPP8/9 inhibition induced apoptosis, as evidenced by activated form of PARP, caspases-3 and was suppressed by the pan-caspase inhibitor Z-VAD-FMK. Taken together, these results indicate that DPP8 is a novel therapeutic target for myeloma treatment.


Sujet(s)
Antinéoplasiques/usage thérapeutique , Dipeptidases/antagonistes et inhibiteurs , Myélome multiple/traitement médicamenteux , Inhibiteurs de protéases/usage thérapeutique , Animaux , Antinéoplasiques/pharmacologie , Apoptose/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Dipeptidases/métabolisme , Découverte de médicament , Femelle , Humains , Souris , Souris de lignée NOD , Myélome multiple/métabolisme , Myélome multiple/anatomopathologie , Inhibiteurs de protéases/pharmacologie
10.
Mol Clin Oncol ; 11(5): 474-482, 2019 Nov.
Article de Anglais | MEDLINE | ID: mdl-31620278

RÉSUMÉ

The serum soluble interleukin 2 receptor (sIL2R) level is elevated in patients with most types of lymphoid neoplasms, and is also elevated in patients with solid tumors or reactive conditions, such as severe inflammation. To evaluate the diagnostic significance of sIL2R levels for the screening and differential diagnosis of lymphomas, data from 248 consecutive adult patients with suspected lymphoma were retrospectively analyzed in order to determine its diagnostic characteristics and the clinical parameters that affect diagnosis. In 133 patients with aggressive or indolent lymphomas or related neoplasms, the sIL2R level was higher (median: 920 U/ml, standard deviation: 7,312 U/ml) compared with that of 115 patients with other diagnoses (median: 520 U/ml, standard deviation: 727 U/ml), including solid tumors, infection, inflammation, and others. When the cutoff value of sIL2R was 1,104 U/ml, the specificity was 80%, at which point lymphoma was suspected. When the threshold levels were increased from 1,500 to 2,000 U/ml, the specificity increased from 87 to 93%, with the positive likelihood ratio increasing from 2.99 to 4.97, strongly suggesting the diagnosis of lymphoma. The receiver operating characteristic curve for prediction of lymphoma by sIL2R revealed that the area under the curve was 0.695. The curve was nearest to the left corner of the plot when the threshold was 1,946 U/ml; at this point, the sensitivity, specificity and positive likelihood ratio were 35%, 93% and 5.06, respectively. Multivariate analysis demonstrated that an age >46 years and lactate dehydrogenase level >173 U/l appeared to increase the risk of malignant lymphoma diagnosis. Although sIL2R appears to be a less specific marker for the screening of lymphomas, its detection at higher levels strongly suggests the diagnosis of lymphomas. Therefore, sIL2R may be more useful compared with any other parameter for lymphoma diagnosis, provided other false-positive conditions are taken into consideration.

11.
Medicine (Baltimore) ; 97(23): e10950, 2018 Jun.
Article de Anglais | MEDLINE | ID: mdl-29879041

RÉSUMÉ

RATIONALE: Factor X (FX) deficiency is a rare autosomal recessive bleeding disorder. The majority of patients carry a missense mutation in F10, and patients with bleeding disorders are either homozygous or compound heterozygous for F10. Nonsense mutations are exceptionally rare, and a heterozygous nonsense mutation is not considered to cause bleeding disorders. PATIENT CONCERNS: A 35-year-old Japanese female with an incidental hemorrhage after gynecologic polypectomy was referred to our hospital. DIAGNOSES: Following differential diagnostic workup, including cross-mixing test, congenital FX deficiency was strongly suspected. INTERVENTION: Coagulation tests and mutation analyses were conducted for the patient and her parents. OUTCOMES: Mutation analysis revealed that she carried a heterozygous nonsense mutation in F10. Pedigree analysis revealed that the mutation was inherited from her mother although there was no familial history of bleeding or hemostatic disturbance. LESSONS: Hemostatic disturbance may occur even in a patient with heterozygous F10. Because heterozygous nonsense mutation in F10 is expected to be hidden in an apparently healthy population, as observed in our patient, unexpected hemostatic disturbance may occur, particularly during the use of direct oral anticoagulant (DOAC)-targeting factor Xa for thrombotic diseases. FX activity should be evaluated before prescribing DOACs to patients.


Sujet(s)
Codon non-sens/génétique , Déficit en facteur X/génétique , Hétérozygote , Hémorragie utérine/génétique , Adulte , Femelle , Procédures de chirurgie gynécologique/effets indésirables , Humains , Pedigree , Polypes/chirurgie , Maladies du col utérin/chirurgie
12.
Case Rep Gastroenterol ; 12(3): 699-703, 2018.
Article de Anglais | MEDLINE | ID: mdl-30631255

RÉSUMÉ

According to the literature, spontaneous remission of aggressive lymphomas is extremely rare; gastric non-Hodgkin lymphomas, such as mucosa-associated lymphoid tissue lymphomas, often regress due to Helicobacter pylori treatment or no progression, even in a watch-and-wait strategy. Although spontaneous remission of diffuse large B cell lymphomas in the stomach was very rarely reported, the follow-up periods of the cases of spontaneous remission are within 2 years and most cases are likely to relapse after the first remission. Here, we report that a diffuse large B cell lymphoma in the stomach showed spontaneous remission within 2 months after the initial diagnosis and the remission is still continuing for 10 years without any specific treatments against this aggressive lymphoma.

13.
Intern Med ; 56(4): 395-400, 2017.
Article de Anglais | MEDLINE | ID: mdl-28202860

RÉSUMÉ

Hepatic sinusoidal obstruction syndrome (SOS), a serious complication that mainly occurs after hematopoietic-stem cell transplantation (HSCT), is caused by damage to the sinusoidal endothelial cells after the obstruction of the sinusoid. Recently, hepatic SOS was reported to occur after non-HSCT chemotherapies. This report describes a patient who experienced hepatic SOS after non-HSCT chemotherapy for non-Hodgkin lymphoma. A liver biopsy showed the slight dilatation of the hepatic sinusoid, which may be indicative of hepatic SOS. Hepatic SOS should be included in the differential diagnosis of patients with severe liver injury following the administration of chemotherapy regimens that are toxic to the vascular endothelial cells.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Maladie veno-occlusive hépatique/induit chimiquement , Lymphome B diffus à grandes cellules/traitement médicamenteux , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Biopsie , Issue fatale , Transplantation de cellules souches hématopoïétiques , Maladie veno-occlusive hépatique/imagerie diagnostique , Maladie veno-occlusive hépatique/anatomopathologie , Humains , Foie/anatomopathologie , Mâle , Adulte d'âge moyen , Tomodensitométrie
14.
Angle Orthod ; 87(4): 563-569, 2017 Jul.
Article de Anglais | MEDLINE | ID: mdl-28206811

RÉSUMÉ

OBJECTIVE: To investigate how types of tooth movement, bodily or tipping, influence the displacement of the center of resistance in teeth and alveolar bone resorption. MATERIALS AND METHODS: Ten-week-old female Wistar rats were divided into eight groups of different factors, as follows: type of movement (bodily and tipping) and force magnitude (10, 25, 50, and 100 cN). The maxillary left first molars were moved mesially with nickel-titanium coil springs for 28 days. Micro-computed tomography (micro-CT) images were taken before and after tooth movement. The position of the center of resistance was determined by using finite element models constructed from the micro-CT image. The displacement of the center of resistance and the volume of alveolar bone resorption were measured. RESULTS: The displacement of the center of resistance showed no significant difference between the bodily and tipping groups. The displacements of the center of resistance were increased with force magnitude at 10 and 25 cN, whereas they were not further increased at 50 and 100 cN. On the other hand, cervical alveolar bone resorption was significantly greater in the tipping group than in the bodily group. CONCLUSIONS: Displacement of the center of resistance was not influenced by the types of tooth movement. However, volume of cervical alveolar bone resorption was greater in the tipping movement group than in the bodily movement group.


Sujet(s)
Résorption alvéolaire/imagerie diagnostique , Mouvement dentaire/méthodes , Animaux , Analyse des éléments finis , Modèles animaux , Molaire/imagerie diagnostique , Nickel , Fils orthodontiques , Rat Wistar , Titane , Microtomographie aux rayons X
15.
Eur J Orthod ; 39(3): 277-286, 2017 06 01.
Article de Anglais | MEDLINE | ID: mdl-27141933

RÉSUMÉ

Objectives: The purpose of this study was to evaluate the relationships among the volume of bone cut during corticotomy, amount of tooth movement, volume of root resorption, and volume of the resultant alveolar bone resorption after tooth movement. Methods: Ten-week-old female Wistar rats were distributed into the corticotomy groups and a control group that underwent sham corticotomy. Two experiments employing two different orthodontic forces (10 or 25g) and experimental periods (14 or 21 days) were performed. The volumes of the bone cut by corticotomy were 0.1, 1.0, and 1.7mm3 in the 25g groups, and 1.0 and 1.7mm3 in the 10g groups. Nickel-titanium closed-coil springs were set on the maxillary left first molars to induce mesial movement. After orthodontic tooth movement, the amount of tooth movement, volume of root resorption, and volume of alveolar bone resorption were measured. Results: Despite differences in the volume of bone cut among the different corticotomy groups, there were not significant differences in the amount of tooth movement and volume of root resorption between the control group and any of the corticotomy groups. However, higher volume of bone cut during corticotomy was significantly related to the decreased alveolar bone volume-in particular, to the reduced height of the alveolar bone crest after tooth movement. Conclusions: The volume of the alveolar bone cut during corticotomy does not affect tooth movement or root resorption in 10-week-old female Wistar rats; however, it may increase alveolar bone loss after tooth movement.


Sujet(s)
Résorption alvéolaire/étiologie , Processus alvéolaire/chirurgie , Os cortical/chirurgie , Rhizalyse/étiologie , Mouvement dentaire/méthodes , Résorption alvéolaire/anatomopathologie , Processus alvéolaire/anatomopathologie , Animaux , Os cortical/anatomopathologie , Femelle , Molaire , Rat Wistar , Mouvement dentaire/effets indésirables
16.
Carcinogenesis ; 37(11): 1098-1109, 2016 Nov 01.
Article de Anglais | MEDLINE | ID: mdl-27559111

RÉSUMÉ

Mesotheliomas are frequently characterized by disruption of Hippo pathway due to deletion and/or mutation in genes, such as neurofibromin 2 ( NF2 ). Hippo disruption attenuates yes-associated protein (YAP) phosphorylation allowing YAP to translocate to the nucleus and regulate gene expression. The role of disrupted Hippo pathway in maintenance of established mesotheliomas has been extensively investigated using cell lines; however, its involvement in development of human mesothelioma has not been explored much. Here, we employed immortalized human mesothelial cells to disrupt Hippo pathway. YAP phosphorylation was reduced on NF2 knockdown and the cells exhibited altered growth in vitro , developing tumors when transplanted into nude mice. Similar results were obtained from enforced expression of wild-type or constitutively active (S127A) YAP, indicating the crucial role of activated YAP in the transformation of mesothelial cells. Gene expression analysis comparing control- and YAP-transduced immortalized human mesothelial cells revealed phospholipase-C beta 4 ( PLCB4 ) to be among the genes highly upregulated by YAP. PLCB4 was upregulated by YAP in immortalized human mesothelial cells and downregulated on YAP knockdown in Hippo-disrupted mesothelioma cell lines. PLCB4 knockdown attenuated the growth of YAP-transduced immortalized mesothelial cells and YAP-active, but not YAP-nonactive, mesothelioma cell lines. Our model system thus provides a versatile tool to investigate the mechanisms underlying mesothelioma development. We suggest that PLCB4 may be an attractive drug target for the treatment of mesothelioma.

17.
Cancer Res ; 74(21): 6129-38, 2014 Nov 01.
Article de Anglais | MEDLINE | ID: mdl-25320005

RÉSUMÉ

Adult T-cell leukemia/lymphoma (ATL) is a human T-cell leukemia virus type-1-induced neoplasm with four clinical subtypes: acute, lymphoma, chronic, and smoldering. Although the chronic type is regarded as indolent ATL, about half of the cases progress to acute-type ATL. The molecular pathogenesis of acute transformation in chronic-type ATL is only partially understood. In an effort to determine the molecular pathogeneses of ATL, and especially the molecular mechanism of acute transformation, oligo-array comparative genomic hybridization and comprehensive gene expression profiling were applied to 27 and 35 cases of chronic and acute type ATL, respectively. The genomic profile of the chronic type was nearly identical to that of acute-type ATL, although more genomic alterations characteristic of acute-type ATL were observed. Among the genomic alterations frequently observed in acute-type ATL, the loss of CDKN2A, which is involved in cell-cycle deregulation, was especially characteristic of acute-type ATL compared with chronic-type ATL. Furthermore, we found that genomic alteration of CD58, which is implicated in escape from the immunosurveillance mechanism, is more frequently observed in acute-type ATL than in the chronic-type. Interestingly, the chronic-type cases with cell-cycle deregulation and disruption of immunosurveillance mechanism were associated with earlier progression to acute-type ATL. These findings suggested that cell-cycle deregulation and the immune escape mechanism play important roles in acute transformation of the chronic type and indicated that these alterations are good predictive markers for chronic-type ATL.


Sujet(s)
Cycle cellulaire/génétique , Régulation de l'expression des gènes tumoraux/génétique , Leucémie-lymphome à cellules T de l'adulte/génétique , Protéines tumorales/biosynthèse , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Antigènes CD58/biosynthèse , Inhibiteur p16 de kinase cycline-dépendante/biosynthèse , Évolution de la maladie , Femelle , Analyse de profil d'expression de gènes , Humains , Leucémie-lymphome à cellules T de l'adulte/anatomopathologie , Mâle , Adulte d'âge moyen
18.
Cancer Sci ; 105(7): 897-904, 2014 Jul.
Article de Anglais | MEDLINE | ID: mdl-24815991

RÉSUMÉ

Clonal heterogeneity in lymphoid malignancies has been recently reported in adult T-cell lymphoma/leukemia, peripheral T-cell lymphoma, not otherwise specified, and mantle cell lymphoma. Our analysis was extended to other types of lymphoma including marginal zone lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. To determine the presence of clonal heterogeneity, 332 cases were examined using array comparative genomic hybridization analysis. Results showed that incidence of clonal heterogeneity varied from 25% to 69% among different types of lymphoma. Survival analysis revealed that mantle cell lymphoma and diffuse large B-cell lymphoma with clonal heterogeneity showed significantly poorer prognosis, and that clonal heterogeneity was confirmed as an independent predictor of poor prognosis for both types of lymphoma. Interestingly, 8q24.1 (MYC) gain, 9p21.3 (CDKN2A/2B) loss and 17p13 (TP53, ATP1B2, SAT2, SHBG) loss were recurrent genomic lesions among various types of lymphoma with clonal heterogeneity, suggesting at least in part that alterations of these genes may play a role in clonal heterogeneity.


Sujet(s)
Lymphomes/génétique , Lymphomes/mortalité , Lymphomes/anatomopathologie , Lymphome de Burkitt/génétique , Lymphome de Burkitt/mortalité , Lymphome de Burkitt/anatomopathologie , Chromosomes humains de la paire 8 , Hybridation génomique comparative , Inhibiteur p16 de kinase cycline-dépendante/génétique , Délétion de gène , Dosage génique , Humains , Lymphome B de la zone marginale/génétique , Lymphome B de la zone marginale/mortalité , Lymphome B de la zone marginale/anatomopathologie , Lymphome folliculaire/génétique , Lymphome folliculaire/mortalité , Lymphome folliculaire/anatomopathologie , Lymphome B diffus à grandes cellules/génétique , Lymphome B diffus à grandes cellules/mortalité , Lymphome B diffus à grandes cellules/anatomopathologie , Pronostic
19.
Angle Orthod ; 84(6): 1079-85, 2014 Nov.
Article de Anglais | MEDLINE | ID: mdl-24754797

RÉSUMÉ

OBJECTIVE: To investigate differences in the amount of tooth movement and root resorption that occurred after tipping and bodily movement of the maxillary first molar in rats. MATERIALS AND METHODS: Ten-week-old female Wistar rats were divided into two groups according to type of tooth movement and subdivided into four subgroups according to the magnitude of applied force. Nickel-titanium closed-coil springs exerting forces of 10, 25, 50, or 100 g were applied to the maxillary left first molars to induce mesial tooth movement. We designed a novel orthodontic appliance for bodily tooth movement. Tooth movement distance and root resorption were measured using microcomputed tomography and scanning electron and scanning laser microscopy. RESULTS: The amount of tooth movement in the bodily tooth movement group was less than half that in the tipping tooth movement group. The greatest amount of tooth movement occurred in the 10-g tipping and 50-g bodily tooth movement subgroups, and the amount of tooth movement decreased with the application of an excessive magnitude of force. Conversely, root resorption increased when the heavier orthodontic force was applied in both groups. Root resorption in the tipping tooth movement group was approximately twice that in the bodily tooth movement group. CONCLUSIONS: Root resorption in the tipping tooth movement group was more pronounced than that in the bodily tooth movement group. Although the amount of tooth movement decreased when extremely heavy forces were applied, root resorption increased in both the tipping and bodily tooth movement groups in rats.


Sujet(s)
Molaire/anatomopathologie , Rhizalyse/étiologie , Mouvement dentaire/classification , Animaux , Alliage dentaire/composition chimique , Femelle , Imagerie tridimensionnelle/méthodes , Maxillaire , Microscopie confocale , Microscopie électronique à balayage , Nickel/composition chimique , Procédures d'ancrage orthodontique/instrumentation , Conception d'appareil orthodontique , Fils orthodontiques , Rats , Rat Wistar , Contrainte mécanique , Titane/composition chimique , Couronne dentaire/anatomopathologie , Mouvement dentaire/effets indésirables , Racine dentaire/anatomopathologie , Microtomographie aux rayons X/méthodes
20.
Exp Hematol ; 41(8): 731-741.e9, 2013 Aug.
Article de Anglais | MEDLINE | ID: mdl-23583576

RÉSUMÉ

Evidence is accumulating that hematologic malignancies develop following acquisition of multiple genetic changes. Despite providing many insights into the way by which given genetic changes contribute to the development of disease, the generation of animal models is often laborious. We show a simplified method that allows the retroviral transduction of genes of interest into mouse B or T cells, thus leading to the rapid generation of models of lymphoid neoplasm in mice. Specifically, germinal center B cells induced in vitro from naive mouse B cells and infected with retroviruses for Myc and Bcl2 rapidly developed a neoplasm of immunoglobulin-expressing mature B cells in transplanted mice. Likewise, T cells induced in vitro from immature hematopoietic cells and infected with retroviruses for Myc, Bcl2, and Ccnd1 rapidly developed CD4(+)CD8(-) and CD4(+)CD8(+) T cell neoplasm in transplanted mice. These findings support the use of our simplified method as a versatile tool for lymphoma research.


Sujet(s)
Lymphocytes B/anatomopathologie , Modèles animaux de maladie humaine , Lymphomes/génétique , Retroviridae/génétique , Lymphocytes T/anatomopathologie , Transduction génétique , Animaux , Cycline D1/génétique , Gènes bcl-2 , Gènes myc , Vecteurs génétiques , Techniques in vitro , Lymphomes/anatomopathologie , Souris
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE